<?xml version='1.0' encoding='utf-8'?>
<document id="30952677"><sentence text="Rolapitant Is a Reversible Inhibitor of CYP2D6." /><sentence text="Rolapitant [(Varubi), 5S,8S)-8-[[(1R)-1-[3,5 bis(trifluoromethyl phenyl]ethoxy]methyl]-8-phenyl-1,7-diazaspiro[4" /><sentence text="5]decan-2-one] is a high-affinity NK1 receptor antagonist that was approved in September 2015 as a treatment for nausea and vomiting caused by chemotherapy"><entity charOffset="0-13" id="DDI-PubMed.30952677.s3.e0" text="5]decan-2-one" /></sentence><sentence text=" In vivo rolapitant moderately inhibits CYP2D6 for at least 7 days after one 180 mg dose" /><sentence text=" Due to the long inhibition time, we investigated rolapitant as a possible mechanism-based inactivator of CYP2D6" /><sentence text=" Rolapitant docked in the active site of CYP2D6 and displayed type I binding to CYP2D6 with a Ks value of 1" /><sentence text="2 ± 0" /><sentence text="4 µM" /><sentence text=" However, in NADPH-, time-, and concentration-dependent assays of CYP2D6 activity, no evidence for mechanism-based inactivation and no metabolites of rolapitant were observed"><entity charOffset="13-19" id="DDI-PubMed.30952677.s9.e0" text="NADPH-" /></sentence><sentence text=" Stopped-flow binding studies yielded a kon /koff (Kd) value of 6" /><sentence text="2 µM" /><sentence text=" The IC50 value for rolapitant inhibition of CYP2D6 activity was 24 µM, suggesting that inhibition is not due to tight binding of rolapitant to CYP2D6" /><sentence text=" By Lineweaver-Burk analysis, rolapitant behaved as a mixed, reversible inhibitor" /><sentence text=" The Ki values of 20 and 34 µM were determined by Dixon analysis, with bufuralol and dextromethorphan as reporter substrates, respectively, and drug-drug interaction modeling did not predict the reported in vivo inhibition"><entity charOffset="71-80" id="DDI-PubMed.30952677.s14.e0" text="bufuralol" /><entity charOffset="85-101" id="DDI-PubMed.30952677.s14.e1" text="dextromethorphan" /><pair ddi="false" e1="DDI-PubMed.30952677.s14.e0" e2="DDI-PubMed.30952677.s14.e0" /><pair ddi="false" e1="DDI-PubMed.30952677.s14.e0" e2="DDI-PubMed.30952677.s14.e1" /></sentence><sentence text=" The interaction of rolapitant with CYP2D6 was also examined in 1 microsecond molecular dynamics simulations" /><sentence text=" Rolapitant adopted multiple low-energy binding conformations near the active site, but at distances not consistent with metabolism" /><sentence text=" Given these findings, we do not see evidence that rolapitant is a mechanism-based inactivator" /><sentence text=" Moreover, the reversible inhibition of CYP2D6 by rolapitant may not fully account for the moderate inhibition described in vivo" /><sentence text="" /></document>